多发性骨髓瘤未来发展方向及最新进展

英杰 吴, 红梅 马

摘要


多发性骨髓瘤（MM）是一种在骨髓中发生的浆细胞增生的恶性肿瘤，其特征是骨髓中恶性浆细胞（BM）的克隆增殖、溶骨性病变和免疫缺陷，与血液或尿液中的单克隆蛋白相关，占所有癌症的 1%，约占所有血液系统恶性肿瘤的 10%。尽管在过去的十年中，其总生存期逐步改善，但其特点仍然是复发、缓解持续时间逐步缩短和无治疗间隔。虽然这种疾病仍然无法治，但未来的前景是在所有可用药物中找到最佳的治疗组。

关键词


多发性骨髓瘤；肾功能不全；发病机制；治疗

全文:

PDF

参考


Rajkumar S V. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management[J]. Am J Hematol, 2022 Aug;97(8):1086-1107.

Padala S A, Barsouk A, Barsouk A, et al. Epidemiology, Staging, and Management of Multiple Myeloma[J]. Med Sci(Basel), 2021,Jan 20;9(1):3.

huyan B, Padhi S, Das P K, et al. Hypercalcemia (C), renal dysfunction (R), anemia (A), and lytic bone lesion(B)(CRAB) as presenting features in non myelomatous malignancies: A case report and review of the literature[J]. Int J Lab Hematol, 2022 Oct;44(5):e198-e203.

Van de Donk NWCJ, Pawlyn C, Yong K L. Multiple myeloma[J]. Lancet, 2021 Jan 30;397(10272):410-427.

Dao A, McDonald MM, Savage PB, et al. Preventing osteolytic lesions and osteomyelitis in multiple myeloma[J]. J Bone Oncol. 2022 Oct 28;37:100460.

anaroni C,Yee A J, Raje N S. Myeloma and Bone Disease[J]. Curr Osteoporos Rep, 2017 Oct;15(5):483-498.

Cowan A J, Green D J, Kwok M, et al. Diagnosis and Management of Multiple Myeloma: A Review[J]. JAMA .2022 Feb 1;327(5):464-477.

Yang P, Qu Y, Wang M, et al. Pathogenesis and treatment of multiple myeloma[J]. MedComm (2020), 2022 Jun 2;3(2):e146.

Brigle K, Rogers B. Pathobiology and Diagnosis of Multiple Myeloma[J]. Semin Oncol Nurs, 2017 Aug;33(3):225-236.

Neuse C J, Lomas O C, Schliemann C, et al. Genome instability in multiple myeloma[J]. Leukemia, 2020 Nov;34(11):2887-2897.

Goldman-Mazur S, Jurczyszyn A, Castillo J J, et al. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma[J]. Am J Hematol, 2020 May;95(5):503-509.

Vrábel D, Pour L, Ševčíková S. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma[J]. Blood Rev, 2019 Mar;34:56-66.

Ho M, Xiao A, Yi D, et al. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment[J]. Curr Oncol, 2022 Nov 21;29(11):8975-9005.

Ria R, Vacca A. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma[J]. Int J Mol Sci, 2020 Jan 17;21(2):613.

Gavriatopoulou M, Malandrakis P, Ntanasis-Stathopoulos I, et al. Nonselective proteasome inhibitors in multiple myeloma and future perspectives[J]. Expert Opin Pharmacother, 2022 Feb;23(3):335-347.

Manasanch E E, Orlowski R Z. Proteasome inhibitors in cancer therapy[J]. Nat Rev Clin Oncol, 2017 Jul;14(7):417-433.

Albornoz N, Bustamante H, Soza A, et al. Cellular Responses to Proteasome Inhibition: Molecular Mechanisms and Beyond[J]. Int J Mol Sci, 2019 Jul 10;20(14):3379.

Narayanan S, Cai C Y, Assaraf Y G, et al. Targeting the ubiquitin- proteasome pathway to overcome anti-cancer drug resistance[J]. Drug Resist Updat, 2020 Jan;48:100663.

Ito S. Proteasome Inhibitors for the Treatment of Multiple Myeloma[J]. Cancers (Basel), 2020 Jan 22;12(2):265.

Asatsuma-Okumura T, Ito T, Handa H. Molecular mechanisms of cereblon-based drugs[J]. Pharmacol Ther, 2019 Oct;202:132-139.

Tacchetti P, Pantani L, Patriarca F, et al. Bortezomib, thalidomide,and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006):long-term follow- up analysis of a randomised phase 3,open-label study[J]. Lancet Haematol, 2020 Dec;7(12):e861-e873.

Richardson P G, Siegel D S, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma:a randomized phase 2 study[J]. Blood, 2014 Mar 20;123(12):1826-1832.

Baz R C, Martin T G 3rd, Lin H Y, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma[J]. Blood, 2016 May 26;127(21):2561-2568.

Morandi F, Airoldi I, Marimpietri D, et al. CD38, a Receptor with Multifunctional Activities:From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles,to a Target for Therapeutic Strategies[J].Cells, 2019 Nov 27,8(12):1527.

Bonello F, D’Agostino M, Moscvin M, et al. CD38 as an immunotherapeutic target in multiple myeloma[J]. Expert Opin Biol Ther, 2018 Dec;18(12):1209-1221.

Hill E Morrison C, Kazandjian D. Daratumumab: A review of current indications and future directions[J]. Semin Oncol, 2022 Feb;49(1):48-59.

Lonial S, Weiss B M, Usmani S Z, et al. Daratumumab

Goldsmith S R, Liu L, Covut F. Isatuximab for the treatment of multiple myeloma[J].Drugs Today (Barc), 2021 Nov;57(11):665-675.

Moreau P, Dimopoulos M A, Mikhael J, et al. Isatuximab,

Grosicki S, Bednarczyk M, Barchnicka A, et al. Elotuzumab in the treatment of relapsed and refractory multiple myeloma[J]. Future Oncol, 2021 May;17(13):1581-1591.

Passey C, Sheng J, Mora J, et al. The Clinical Pharmacology of Elotuzumab[J]. Clin Pharmacokinet, 2018 Mar;57(3):297-313.

Ohmine K, Uchibori R. Novel immunotherapies in multiple myeloma[J]. Int J Hematol, 2022 Jun;115(6):799-810.

Maude S L, Laetsch T W, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia[J]. N Engl J Med, 2018 Feb 1;378(5):439-448.

Martino M, Canale F A, Alati C, et al. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma[J]. Cancers (Basel), 2021 May 27;13(11):2639.

Yang Q, Li X, Zhang F, et al. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis[J]. Int J Med Sci, 2021 Feb 18;18(8):1786-1797.

Yu W D, Sun G Li J, et al. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy[J]. Cancer Lett, 2019 Jun 28;452:66-70.

Topp M S, Duell J, Zugmaier G, et al. Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma[J]. J Clin Oncol, 2020 Mar 10;38(8):775-783.

Lopes R, Ferreira B V, Caetano J, et al. Boosting Immunity against Multiple Myeloma[J]. Cancers (Basel), 2021 Mar 11;13(6):1221.

De Luca F, Allegra A, Di Chio C, et al. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma[J]. Int J Mol Sci, 2023 Feb 5;24(4):3136.

Lonial S, Lee H C, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two- arm,randomised,open-label, phase 2 study[J]. Lancet Oncol, 2020 Feb;21(2):207-221.




DOI: https://doi.org/10.12346/pmr.v5i3.8536

Refbacks

  • 当前没有refback。